Antibody–drug conjugates: targeted drug delivery for cancerStephen C. Alley, Peter D. Senter, Nicole M. Okeley|Current Opinion in Chemical Biology|2010Cited by 651
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicitySvetlana O. Doronina, Peter D. Senter, Brian A. Mendelsohn et al.|Bioconjugate Chemistry|2005Cited by 511
Contribution of Linker Stability to the Activities of Anticancer ImmunoconjugatesStephen C. Alley, Peter D. Senter, Dennis R. Benjamin et al.|Bioconjugate Chemistry|2008Cited by 464
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug ConjugateNicole M. Okeley, Stephen C. Alley, Jamie B. Miyamoto et al.|Clinical Cancer Research|2010Cited by 386
Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody DisulfidesMichael Sun, Stephen C. Alley, Kevin S. Beam et al.|Bioconjugate Chemistry|2005Cited by 365